
Affinity Asset Advisors, LLC
About Affinity Asset Advisors, LLC’s 13F portfolio
Affinity Asset Advisors, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Affinity Asset Advisors, LLC reported $2.0B across 104 US-listed positions (). Its largest position is ROIVANT SCIENCES LTD (ROIV) at 6.5% of the reported book, and its ten biggest holdings make up 43% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: ROIV ROIVANT SCIENCES LTD | — — | 6.5% | 3.8M | $132.7M |
| 2 | NASDAQ: APGE APOGEE THERAPEUTICS INC | — — | 6.4% | 987K | $131.0M |
| 3 | NASDAQ: SYRE SPYRE THERAPEUTICS INC | — — | 5.6% | 1.3M | $113.6M |
| 4 | NASDAQ: XENE XENON PHARMACEUTICALS INC | — — | 4.7% | 1.6M | $96.3M |
| 5 | NASDAQ: ERAS ERASCA INC | — — | 4.7% | 5.3M | $96.2M |
| 6 | NASDAQ: INSM INSMED INC | — — | 3.4% | 650K | $69.3M |
| 7 | NASDAQ: PRAX PRAXIS PRECISION MEDICINES I | — — | 3.0% | 185K | $61.9M |
| 8 | NASDAQ: ALKS ALKERMES PLC | — — | 2.9% | 1.1M | $58.9M |
| 9 | NASDAQ: ORKA ORUKA THERAPEUTICS INC | — — | 2.7% | 590K | $56.2M |
| 10 | NASDAQ: ANAB ANAPTYSBIO INC | — — | 2.7% | 826K | $55.8M |
| 11 | NASDAQ: AVTX AVALO THERAPEUTICS INC | — — | 2.6% | 2.9M | $53.6M |
| 12 | NASDAQ: CYTK CYTOKINETICS INC | — — | 2.3% | 550K | $46.9M |
| 13 | NASDAQ: RVMD REVOLUTION MEDICINES INC | — — | 2.3% | 250K | $46.8M |
| 14 | NASDAQ: ABVX ABIVAX SA | — — | 2.2% | 330K | $44.0M |
| 15 | NASDAQ: TRAX FIRST TRACKS BIOTHERAPEUTICS | — — | 2.0% | 2.0M | $40.9M |
| 16 | NASDAQ: DNTH DIANTHUS THERAPEUTICS INC | — — | 1.9% | 400K | $39.0M |
| 17 | NASDAQ: STRO SUTRO BIOPHARMA INC | — — | 1.9% | 1.2M | $38.9M |
| 18 | NASDAQ: NUVL NUVALENT INC | — — | 1.7% | 275K | $34.0M |
| 19 | NASDAQ: TRVI TREVI THERAPEUTICS INC | — — | 1.6% | 1.8M | $33.6M |
| 20 | NASDAQ: OVID OVID THERAPEUTICS INC | — — | 1.3% | 10.1M | $27.3M |
| 21 | NASDAQ: LXEO LEXEO THERAPEUTICS INC | — — | 1.3% | 5.8M | $27.0M |
| 22 | NASDAQ: CLDX CELLDEX THERAPEUTICS INC NEW | — — | 1.3% | 700K | $26.0M |
| 23 | NASDAQ: BLTE BELITE BIO INC | — — | 1.2% | 165K | $25.4M |
| 24 | NASDAQ: ELVN ENLIVEN THERAPEUTICS INC | — — | 1.2% | 500K | $25.4M |
| 25 | NASDAQ: FBRX FORTE BIOSCIENCES INC | — — | 1.2% | 1.1M | $24.3M |
Showing 1–25 of 104 positions on this page reported in this 13F.
- Healthcare93%
- Financial Services0.1%
- AddedROIVROIVANT SCIENCES LTD+33.9%$132.7M
- AddedINSMINSMED INC+35.4%$69.3M
- AddedPRAXPRAXIS PRECISION MEDICINES I+8.8%$61.9M
- AddedORKAORUKA THERAPEUTICS INC+18.1%$56.2M
- AddedAVTXAVALO THERAPEUTICS INC+116%$53.6M
- AddedRVMDREVOLUTION MEDICINES INC+150%$46.8M
- NewTRAXFIRST TRACKS BIOTHERAPEUTICS—$40.9M
- AddedDNTHDIANTHUS THERAPEUTICS INC+14.3%$39.0M
- AddedSTROSUTRO BIOPHARMA INC+9.6%$38.9M
- AddedLXEOLEXEO THERAPEUTICS INC+15.0%$27.0M
- ReducedAPGEAPOGEE THERAPEUTICS INC−23.2%$131.0M
- ReducedXENEXENON PHARMACEUTICALS INC−4.8%$96.3M
- ReducedERASERASCA INC−1.9%$96.2M
- ReducedALKSALKERMES PLC−16.7%$58.9M
- ReducedANABANAPTYSBIO INC−12.1%$55.8M
- ReducedCYTKCYTOKINETICS INC−21.5%$46.9M
- ReducedABVXABIVAX SA−18.5%$44.0M
- ReducedNUVLNUVALENT INC−8.3%$34.0M
- ReducedTRVITREVI THERAPEUTICS INC−10.0%$33.6M
- ReducedOVIDOVID THERAPEUTICS INC−4.6%$27.3M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | LXEO Lexeo Therapeutics, Inc. | 13G | 9.8% · 2 classes | 8.1M | Filed 13 NOV 2026 |
| 2 | RACC Research Alliance Corporation III | 13G | 9.5% | 736K | Filed 13 NOV 2026 |
| 3 | — Ventyx Bioscience, Inc. | 13G | 9.0% | 6.5M | Filed 29 JAN 2026 |
| 4 | VOGX Vogenx, Inc. | 13G | 6.2% | 915K | Filed 13 NOV 2026 |
| 5 | TRAX First Tracks Biotherapeutics, Inc | 13G | 5.8% | 2.0M | Filed 13 AUG 2026 |
| 6 | JSPR Jasper Therapeutics, Inc. | 13G | 5.6% | 1.9M | Filed 13 NOV 2026 |
Showing all 6 disclosed stakes.
Reading Affinity Asset Advisors, LLC’s 13F portfolio
Affinity Asset Advisors, LLC’s $2.0B 13F book is spread across 104 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 43%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are ROIV, APGE, SYRE, XENE and ERAS, led by ROIVANT SCIENCES LTD (ROIV) at 6.5% of the portfolio. The heaviest sector exposure is Healthcare (93%), then Financial Services (0%).
What Affinity Asset Advisors, LLC changed last quarter
Between 2026-03-31 and Q2 2026, Affinity Asset Advisors, LLC was a net buyer: it opened 19 new positions and added to 33 more, while trimming 28 and closing 10 outright. Against a 104-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ROIVANT SCIENCES LTD (ROIV), and its biggest reduction was APOGEE THERAPEUTICS INC (APGE).
What a 13F does and doesn’t reveal
A 13F captures only Affinity Asset Advisors, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Affinity Asset Advisors, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Affinity Asset Advisors, LLC's profile on this page is built directly from those filings.
How current is the 13F data on Affinity Asset Advisors, LLC's page?
It reflects Affinity Asset Advisors, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Affinity Asset Advisors, LLC files its next quarterly report, this page refreshes automatically.
Can I see Affinity Asset Advisors, LLC's complete list of holdings?
This page highlights Affinity Asset Advisors, LLC's largest positions rather than all 104 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Affinity Asset Advisors, LLC's filings.
Does a 13F show everything Affinity Asset Advisors, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Affinity Asset Advisors, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Affinity Asset Advisors, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

